Regeneron Pharmaceuticals, Inc. (REGN), the Tarrytown, New York-based biopharmaceutical company behind blockbusters such as Dupixent and Eylea, has just delivered one of its most consequential quarterly prints in years. After reporting third-quarter 2026 results on Oct. 30, shares surged roughly 13% to close near $928, reaching a two-year high and vaulting above most published Wall Street price targets. That sharp re-rating reframes a question many investors are now asking: can the stock reach the $1,050 level?
The $1,050 objective is best understood as a fallback benchmark rather than a consensus figure. According to data compiled from S&P Global, roughly 28 analysts rate the stock a "Buy" on average, with a mean 12-month target near $869 — a level now about 6% below the current share price. Because the post-earnings rally carried REGN above that average, the average analyst price target no longer offers a meaningful upside reference. The genuine upside question therefore shifts to the highest, most recently updated targets.
Following the third-quarter beat, JPMorgan raised its target to $1,050 from $950, Raymond James to $1,020 from $911, and Piper Sandler to $1,000 from $865. Guggenheim had already moved to $1,030, with TD Cowen at $980 and UBS — which upgraded the stock to Buy in October — at $978. On the more cautious side, Citi (Neutral) sits at $825, Baird (Neutral) at $875, and RBC (Sector Perform) at $810. That dispersion, from the mid-$700s to above $1,000, shows how differently analysts weigh the durability of Dupixent and the promise of Regeneron's pipeline.
With shares near $928, reaching $1,050 would require a gain of about 13%, a substantial but not extreme move for a large-cap biopharma name. Third-quarter results provided the fundamental spark: revenue of $5.12 billion rose 36% year over year, while adjusted EPS (earnings per share) climbed roughly 70% to $20.07, both well ahead of consensus. Dupixent, developed with partner Sanofi, posted record global sales near $6.5 billion, and high-dose Eylea HD grew U.S. revenue 62% to about $699 million.
Notably, however, combined U.S. Eylea sales were still down about 1%, underscoring that the franchise has not fully returned to growth. Some of the quarter's strength also reflected favorable gross-to-net pricing adjustments that may not repeat each period. The path to $1,050 likely requires continued Dupixent momentum, sustained Eylea HD conversion, and incremental pipeline or business-development catalysts.
Several verified factors could underpin further gains. Dupixent's prescription momentum suggests durable underlying demand across its expanding indication set. Eylea HD's rapid conversion demonstrates Regeneron's ability to defend a key franchise against competition. A cash position of $16.2 billion, aggressive share repurchases, and strong free cash flow give management substantial strategic flexibility, including for business development. Analysts at Raymond James specifically argued the time has come for Regeneron to deploy that war chest more aggressively, and they flagged near-term catalysts such as CIDEB MASH data, a potential cemdisiran launch, and an Eylea HD prefilled syringe approval.
The principal obstacle is valuation. After a one-day jump of 13%, REGN trades above the consensus target and roughly 20 times trailing earnings, and the market's fair-value estimates now sit modestly below the share price. Technical conditions are also stretched, with the relative strength index (RSI) in the late 70s — a level often associated with overbought conditions and short-term pullbacks. Leerink Partners and RBC each maintained neutral stances even while acknowledging the quarter's strength, arguing that further upside depends on pipeline success rather than the current commercial franchises. One-time pricing benefits and continued Eylea franchise pressure are additional risks.
REGN broke decisively above its prior September high near $859 to print a new 52-week high of roughly $935. That breakout area now forms a potential support zone on any pullback, while the 52-week low near $591 highlights how far the stock has traveled. The $1,000 level represents the next psychological round number on the way toward $1,050, with the mid-$850s as a first area of interest for buyers on weakness.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms differ. The most important items to watch include upcoming earnings and guidance, revisions to Dupixent and Eylea estimates, clinical readouts across immunology, oncology and metabolic disease, regulatory decisions, and any shift in how analysts interpret the gross-to-net pricing dynamics that boosted the latest quarter.
For traders seeking a more systematic read on names like Regeneron, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning allows, and it can complement fundamental research on a fast-moving name such as REGN.
Reaching $1,050 would require roughly a 13% advance from current levels — a realistic but far-from-guaranteed move that hinges less on Regeneron's core commercial franchises than on its pipeline and capital-deployment decisions. The bullish case rests on exceptional third-quarter execution, record Dupixent sales, and a fortress balance sheet. The bearish case points to a valuation that now exceeds the Street's average target, an overbought technical profile, and a wide analyst range that reflects real uncertainty about how much future growth is already reflected in the price. The $1,050 level is the top of the current analyst range rather than a consensus, and investors should treat it as a milestone to monitor rather than a foregone conclusion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with VRTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then VRTX could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | +13.33% | ||
| VRTX - REGN | 44% Loosely correlated | +3.50% | ||
| EXEL - REGN | 39% Loosely correlated | +4.82% | ||
| RPRX - REGN | 37% Loosely correlated | +1.90% | ||
| BMRN - REGN | 37% Loosely correlated | +1.77% | ||
| ARQT - REGN | 35% Loosely correlated | +0.31% | ||
More | ||||